Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ze-Hui Kok"'
Autor:
Wei Xiang, Colin Sng, Yi-Hui Lam, Ze-Hui Kok, Yeh-Ching Linn, Soek-Ying Neo, Yin-Yin Siew, Deepika Singh, Hwee-Ling Koh, Charles Chuah
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 14, p 7958 (2024)
While BCR::ABL1 tyrosine kinase inhibitors have transformed the treatment paradigm for chronic myeloid leukemia (CML), disease progression and treatment resistance due to BCR::ABL1-dependent and BCR::ABL1-independent mechanisms remain a therapeutic c
Externí odkaz:
https://doaj.org/article/b3e1cebcf53244eab485a851cc5c3a83
Autor:
Verity A Saunders, Wen Tian Sun, Yi Hui Lam, Deborah L. White, Ze Hui Kok, Bee Ling Ng, Wei Xiang, Kartini Asari, Charles Chuah
Publikováno v:
Anti-Cancer Drugs. 32:526-536
The resistance of chronic myeloid leukaemia (CML) to tyrosine kinase inhibitors (TKIs) remains a significant clinical problem. Targeting alternative pathways, such as protein prenylation, is known to be effective in overcoming resistance. Simvastatin
Autor:
Lingzhi Wang, Xiaoqiang Xiang, Qing-Yun Chong, Ngoc-Linh-Chi Bui, Gautam Sethi, Peter E. Lobie, Ze-Hui Kok, Andrea Li Ann Wong, Boon Cher Goh, Wei Peng Yong
Publikováno v:
Pharmacological research. 156
Cell cycle dysregulation, characterised by aberrant activation of cyclin dependent kinases (CDKs), is a hallmark of cancer. After years of research on the first and second generations of less selective CDK inhibitors with unfavourable clinical activi
Autor:
Asaria, Kartini, Wen Tian Sun, Ze Hui Kok, Yi Hui Lam, Bee Ling Ng, Saunders, Verity, White, Deborah L., Chuah, Charles, Wei Xiang
Publikováno v:
Anti-Cancer Drugs; Jun2021, Vol. 32 Issue 5, p526-536, 11p